4.5 Review

The impact of pharmacist interventions on osteoporosis management: a systematic review

Journal

OSTEOPOROSIS INTERNATIONAL
Volume 22, Issue 10, Pages 2587-2596

Publisher

SPRINGER LONDON LTD
DOI: 10.1007/s00198-011-1661-7

Keywords

Osteoporosis; Outcome assessment; Pharmacists; Review; Systematic

Funding

  1. Canadian Institutes of Health Research (CIHR) [CPO-94434]
  2. Leslie Dan Faculty of Pharmacy
  3. CIHR Institute of Health Services and Policy Research Institute

Ask authors/readers for more resources

We completed a systematic review of the literature to examine the impact of pharmacist interventions in improving osteoporosis management. Results from randomized controlled trials suggest that pharmacist interventions may improve bone mineral density testing and calcium intake among patients at high risk for osteoporosis. Introduction Pharmacists play a key role in many healthcare systems by helping patients manage chronic diseases. We completed a systematic review of the literature to identify randomized controlled trials (RCTs) that have examined the impact of pharmacy interventions in narrowing two gaps in osteoporosis management: identifying at-risk individuals and improving adherence to therapy. Methods We searched the electronic databases of EMBASE, HealthStar, International Pharmaceutical Abstracts, MEDLINE, and PubMed from database development to April 2010, examined grey literature, and completed manual searches of reference lists to identify English-language research that examined osteoporosis management interventions within pharmacy practice. Results from RCTs were abstracted and assessed for bias. Results We identified 25 studies that examined pharmacist interventions in osteoporosis management: 16 cohort, 5 cross-sectional, 1 historical/ecological control, and 3 RCTs. RCT interventions included osteoporosis educational and counseling programs, screening by pharmacists based on risk factor assessment or bone mineral density testing, and physician contact or recommendations for patients to follow-up with a general practitioner. Results from the three RCTs suggest that pharmacist interventions may improve bone mineral density testing (targeted screening) and calcium intake among patients at high risk for osteoporosis. However, two of the three RCTs had high risk of bias, and no study examined the impact of pharmacist intervention on osteoporosis treatment adherence. Conclusions Data support the potential role for pharmacists to help reduce gaps in osteoporosis management through improved identification of high-risk patients. More research is needed to examine pharmacist interventions on osteoporosis treatment adherence.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Rheumatology

Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'' by Zheng

Shahab Abtahi, Johanna H. M. Driessen, Andrea M. Burden, Patrick C. Souverein, Joop P. van den Bergh, Tjeerd P. van Staa, Annelies Boonen, Frank de Vries

ANNALS OF THE RHEUMATIC DISEASES (2023)

Letter Rheumatology

Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study' by Gong and Zhang and Lin et al

Shahab Abtahi, Johanna H. M. Driessen, Andrea M. Burden, Patrick C. Souverein, Joop P. van den Bergh, Annelies Boonen

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the Clinical Practice Research Datalink

Shahab Abtahi, Johanna H. M. Driessen, Andrea M. Burden, Patrick C. Souverein, Joop P. van den Bergh, Tjeerd P. van Staa, Annelies Boonen, Frank de Vries

Summary: Low-dose oral glucocorticoid therapy does not increase the overall risk of osteoporotic fractures in patients with RA, but is associated with an increased risk of clinical vertebral fractures.

RHEUMATOLOGY (2022)

Article Public, Environmental & Occupational Health

Assessment of minor health disorders with decision tree-based triage in community pharmacies

Dominik Staempfli, Birgit A. Winkler, Simona Berardi Vilei, Andrea M. Burden

Summary: This study describes the utilization and symptom resolving rate of decision trees for triaging in Swiss community pharmacies. The findings show that pharmacist-led triaging services play an important role in minimizing the burden on other primary health care providers.

RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY (2022)

Article Endocrinology & Metabolism

Site-Specific Fracture Incidence Rates Among Patients With Type 1 Diabetes, Type 2 Diabetes, or Without Diabetes in Denmark (1997-2017)

Annika Vestergaard Kvist, Mohamad I. Nasser, Peter Vestergaard, Morten Frost, Andrea M. Burden

Summary: A study in Denmark from 1997 to 2017 found that the incidence rates of fractures were higher in patients with type 1 and type 2 diabetes compared to those without diabetes, except for foot fractures. The incidence of hip fractures decreased by 35.2%, 47.0%, and 23.4% in patients with type 1 diabetes, type 2 diabetes, and without diabetes, respectively, over the last 5 years. However, vertebral fractures increased by 14.8%, 18.5%, and 38.9% in the same groups. After age adjustment, patients with type 1 diabetes still had a higher risk of fractures compared to those without diabetes, while patients with type 2 diabetes had a risk similar to those without diabetes.

DIABETES CARE (2023)

Article Public, Environmental & Occupational Health

Identification of polypharmacy patterns in new-users of metformin using the Apriori algorithm: A novel framework for investigating concomitant drug utilization through association rule mining

Maria Luisa Faquetti, Adrian Martinez-De la Torre, Theresa Burkard, Guillaume Obozinski, Andrea M. M. Burden

Summary: This study used the Apriori algorithm to analyze patients with polypharmacy who were first-time users of metformin. The most frequently co-prescribed drug with metformin was atorvastatin. Women and older patients were more likely to receive polypharmacy. The results of this study indicate the need to optimize polypharmacy to minimize drug-drug interactions and adverse drug reactions.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2023)

Article Rheumatology

Cancer risk in patients with rheumatoid arthritis treated with janus kinase inhibitors: a nationwide Danish register-based cohort study

Rasmus Westermann, Rene Lindholm Cordtz, Kirsten Duch, Lene Mellemkjaer, Merete Lund Hetland, Andrea Michelle Burden, Lene Dreyer

Summary: This study examined the risk of first primary cancer in patients with rheumatoid arthritis (RA) treated with janus kinase inhibitors (JAKi) compared to those treated with biologic disease-modifying antirheumatic drugs (bDMARDs) in a real-world setting. The results showed that JAKi treatment was not associated with a statistically significant increased risk of first primary cancer compared to bDMARDs treatment in RA patients.

RHEUMATOLOGY (2023)

Article Pharmacology & Pharmacy

An explorative analysis of pharmacovigilance data of oxytocin and its analogue carbetocin, with a focus on haemodynamic adverse effects

Dominik Stampfli, Rebecca Dommrich, Sharon Orbach-Zinger, Andrea M. Burden, Michael Heesen

Summary: This study analyzed the adverse drug events and haemodynamic profile of oxytocin and carbetocin using data from the World Health Organization's pharmacovigilance database. The results showed that carbetocin had a higher reporting of adverse hypertension, hypotension, and tachycardia compared to oxytocin. Therefore, clinicians should be cautious of their patients' susceptibility and the potential haemodynamic deterioration when using these drugs.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2023)

Article Biochemical Research Methods

Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs

Maria Kalweit, Andrea. M. H. Burden, Joschka Boedecker, Thomas H. Hugle, Theresa Burkard

Summary: Machine learning techniques were used to identify five distinct patient groups with rheumatoid arthritis (RA) based on sex, disease burden/duration, and concomitant traditional RA treatment use. The results suggest that different RA patient clusters have different responses to first-line b/tsDMARD treatment.

PLOS COMPUTATIONAL BIOLOGY (2023)

Article Pharmacology & Pharmacy

Comparison of Fracture Identification Using Different Definitions in Healthcare Administrative (Claims) Data

Natalia Konstantelos, Andrea M. Burden, Angela M. Cheung, Sandra Kim, Paul Grootendorst, Suzanne M. Cadarette

Summary: This study aimed to compare fracture rates estimated using different definitions and found that coding decisions have a significant impact on fracture outcome definitions. The study highlights the importance and impact of coding decisions on fracture outcome identification and emphasizes the need for further research to inform best practice in fracture outcome identification.

PHARMACY (2023)

Article Multidisciplinary Sciences

JAK-inhibitors and risk on serious viral infection, venous thromboembolism and cardiac events in patients with rheumatoid arthritis: A protocol for a prevalent new-user cohort study using the Danish nationwide DANBIO register

Maria Luisa Faquetti, Enriqueta Vallejo-Yague, Rene Cordtz, Lene Dreyer, Andrea M. Burden

Summary: Janus Kinase inhibitors (JAKis) are important synthetic drugs used to treat rheumatoid arthritis (RA) patients. However, there have been debates regarding the safety concerns associated with JAKi use, including increased risk for venous thromboembolism (VTE), serious viral infection, and major adverse cardiovascular events (MACE). This study aims to enrich the safety profile of JAKis using real-world data from the Danish DANBIO registry.

PLOS ONE (2023)

Article Medicine, General & Internal

Identification of Medication Prescription Errors and Factors of Clinical Relevance in 314 Hospitalized Patients for Improved Multidimensional Clinical Decision Support Algorithms

Stefan Russmann, Fabiana Martinelli, Franziska Jakobs, Manjinder Pannu, David F. F. Niedrig, Andrea Michelle Burden, Martina Kleber, Markus Bechir

Summary: Potential medication errors and related adverse drug events (ADE) are challenging in clinical medicine. Clinical decision support systems (CDSSs) can help identify preventable prescription errors but often lack specificity. In this study, CDSS performance was analyzed using two systems (pharmaVISTA and MediQ) to evaluate drug-drug interactions and other factors. Automated analyses produced an average of 15.5 alerts per patient, but expert evaluation resulted in only 0.8 recommendations per patient. Co-factors such as comorbidities and laboratory results were decisive for classifying CDSS alerts as clinically relevant.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Endocrinology & Metabolism

Sex- and Age Group-Specific Fracture Incidence Rates Trends for Type 1 and 2 Diabetes Mellitus

Mohamad Nasser, Annika Vestergaard Kvist, Peter Vestergaard, Richard Eastell, Andrea M. Burden, Morten Frost

Summary: The study investigated the trends in fracture incidence rates among men and women with type 1 and type 2 diabetes. The results showed a decrease in fracture incidence rates in men with both types of diabetes and in women with type 2 diabetes, highlighting the need for further attention to the stable trend observed in women with type 1 diabetes.

JBMR PLUS (2023)

Article Rheumatology

Longitudinal associations between body mass index and changes in disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab

Theresa Burkard, Enriqueta Vallejo-Yague, Kim Lauper, Axel Finckh, Thomas Hugle, Andrea M. Burden

Summary: The study found that an increase in BMI may not result in changes in DAS28-esr in patients receiving infliximab, but may lead to a decrease in joint erosions.

RMD OPEN (2023)

No Data Available